< 生产厂家价格 >

舒巴坦钠

舒巴坦钠用途

Sulbactam (CP45899) sodium 是一种竞争性、不可逆的 β-内酰胺酶 (beta-lactamase) 抑制剂。Sulbactam sodium 具有抗菌活性,抑制耐多药不动杆菌-鲍曼不动杆菌复合物。

点击显示

舒巴坦钠名称

[ CAS 号 ]:
69388-84-7

[ 中文名 ]:
舒巴坦钠

[ 英文名 ]:
Sulbactam sodium

[中文别名 ]:

青霉烷砜钠

[英文别名 ]:

SULBACTAM SODIUM SALT
sodium Penicillanate 1,1-Dioxide
SulbactaM SodiuM,USP
sulbacyam sodium
penicillanic acid 1,1-dioxide sodium salt
SODIUM SULBACTAM
EINECS 273-984-4
Sulbatam Sodium
SulbactaM SodiuM API
MFCD01750374

舒巴坦钠生物活性

[ 描述 ]:

Sulbactam (CP45899) sodium 是一种竞争性、不可逆的 β-内酰胺酶 (beta-lactamase) 抑制剂。Sulbactam sodium 具有抗菌活性,抑制耐多药不动杆菌-鲍曼不动杆菌复合物。

[ 相关类别 ]:

研究领域 >> 感染

信号通路 >> 抗感染 >> 细菌

[体外研究]

氨苄西林舒巴坦具有广泛的抗菌活性,包括革兰氏阳性和革兰氏阴性需氧菌和厌氧菌[3]。

[参考文献]

[1]. Noguchi JK, et al. Sulbactam: a beta-lactamase inhibitor. Clin Pharm. 1988;7(1):37-51.

[2]. Lin HS, et al. Sulbactam treatment for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex. Infect Dis (Lond). 2015;47(6):370-378.

[3]. Betrosian AP, et al. Ampicillin-sulbactam: an update on the use of parenteral and oral forms in bacterial infections. Expert Opin Drug Metab Toxicol. 2009;5(9):1099-1112.

舒巴坦钠物理化学性质

[ 沸点 ]:
567.7ºC at 760 mmHg

[ 熔点 ]:
121-123 °C(lit.)

[ 分子式 ]:
C₈H₁₀NNaO₅S

[ 分子量 ]:
255.223

[ 闪点 ]:
297.1ºC

[ 精确质量 ]:
255.017731

[ PSA ]:
102.96000

[ 外观性状 ]:
白色或灰白色结晶粉末

[ 储存条件 ]:
-20°C Freezer, Under Inert Atmosphere

舒巴坦钠毒性和生态

CHEMICAL IDENTIFICATION

RTECS NUMBER :: XH9220000

CHEMICAL NAME :: 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-, 4,4-dioxide, sodium salt, (2S-cis)-

CAS REGISTRY NUMBER :: 69388-84-7

LAST UPDATED :: 199512

DATA ITEMS CITED :: 10

MOLECULAR FORMULA :: C8-H10-N-O2-S.Na

MOLECULAR WEIGHT :: 207.24

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: >6 gm/kg

TOXIC EFFECTS :: Sense Organs and Special Senses (Eye) - ptosis Behavioral - somnolence (general depressed activity)

REFERENCE :: NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 32(Suppl 4),97,1984

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: >6 gm/kg

TOXIC EFFECTS :: Sense Organs and Special Senses (Eye) - ptosis Behavioral - somnolence (general depressed activity)

REFERENCE :: NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 32(Suppl 4),97,1984

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 6500 mg/kg

TOXIC EFFECTS :: Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - respiratory depression

REFERENCE :: NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 32(Suppl 4),97,1984

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: >6 gm/kg

TOXIC EFFECTS :: Sense Organs and Special Senses (Eye) - ptosis Behavioral - somnolence (general depressed activity)

REFERENCE :: NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 32(Suppl 4),97,1984

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: >6 gm/kg

TOXIC EFFECTS :: Sense Organs and Special Senses (Eye) - ptosis Behavioral - somnolence (general depressed activity)

REFERENCE :: NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 32(Suppl 4),97,1984

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 8100 ug/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 17,1106,1986 ** OTHER MULTIPLE DOSE TOXICITY DATA **

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 45500 mg/kg/26W-I

TOXIC EFFECTS :: Liver - changes in liver weight

REFERENCE :: NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 32(Suppl 4),97,1984

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 18 gm/kg/30D-I

TOXIC EFFECTS :: Gastrointestinal - other changes Liver - other changes Liver - changes in liver weight

REFERENCE :: NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 32(Suppl 4),97,1984 ** REPRODUCTIVE DATA **

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intravenous

DOSE :: 13500 mg/kg

SEX/DURATION :: female 17-22 day(s) after conception lactating female 21 day(s) post-birth

TOXIC EFFECTS :: Reproductive - Effects on Newborn - viability index (e.g., # alive at day 4 per # born alive)

REFERENCE :: NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 32(Suppl 4),108,1984

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intravenous

DOSE :: 13500 mg/kg

SEX/DURATION :: female 17-22 day(s) after conception lactating female 21 day(s) post-birth

TOXIC EFFECTS :: Reproductive - Effects on Newborn - weaning or lactation index (e.g., # alive at weaning per # alive at day 4)

REFERENCE :: NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 32(Suppl 4),108,1984

点击显示

舒巴坦钠安全信息

[ 危害码 (欧洲) ]:
Xn: Harmful;

[ 风险声明 (欧洲) ]:
R42/43

[ 安全声明 (欧洲) ]:
S26-S37/39

[ WGK德国 ]:
3

[ 海关编码 ]:
2941109900

舒巴坦钠合成路线

详细合成路线

舒巴坦钠上下游产品

舒巴坦钠上游产品

舒巴坦钠下游产品

舒巴坦钠海关

[ 海关编码 ]: 2941109900

舒巴坦钠文献

Clinical response at Day 3 of therapy and economic outcomes in hospitalized patients with acute bacterial skin and skin structure infection (ABSSSI).

Curr. Med. Res. Opin. 29(7) , 869-77, (2013)

The FDA recently issued guidance for the types of infections that should be included in trials to support an indication for antibacterial treatment. The latest FDA guidance recommends assessing respon...

Antibiotic regimens for management of intra-amniotic infection.

Cochrane Database Syst. Rev. 12 , CD010976, (2014)

Chorioamnionitis is a common infection that affects both mother and infant. Infant complications associated with chorioamnionitis include early neonatal sepsis, pneumonia, and meningitis. Chorioamnion...

Anaerobiospirillum succiniciproducens-induced bacteremia in a healthy man.

Am. J. Emerg. Med. 32(7) , 812.e1-3, (2014)

Anaerobiospirillum succiniciproducens is rarely associated with bacteremia but results in significant mortality. Almost all reported bacteremia cases have occurred in immunocompromised hosts, such as ...

更多文献